학술논문
ABT-450/r- Ombitasvir and Dasabuvir with or without Ribavirin for HCV
Document Type
Report
Author
Ferenci, Peter; Bernstein, David; Lalezari, Jacob; Cohen, Daniel; Luo, Yan; Cooper, Curtis; Tam, Edward; Marinho, Rui T.; Tsai, Naoky; Nyberg, Anders; Box, Terry D.; Younes, Ziad; Enayati, Pedram; Green, Sinikka; Baruch, Yaacov; Bhandari, Bal Raj; Caruntu, Florin Alexandru; Sepe, Thomas; Chulanov, Vladimir; Janczewska, Ewa; Rizzardini, Giuliano; Gervain, Judit; Planas, Ramon; Moreno, Christophe; Hassanein, Tarek; Xie, Wangang; King, Martin; Podsadecki, Thomas; Reddy, K. Rajender
Source
The New England Journal of Medicine. May 22, 2014, Vol. 370 Issue 21, p1983, 10 p.
Subject
Language
English
ISSN
0028-4793
Abstract
The study aims to evaluate the efficacy and safety of ABT-450/r- Ombitasvir and Dasabuvir with or without Ribavirin as a form of treatment for patients with hepatitis C virus (HCV). The results indicate that treatment with these antivral agents was found to be effective for these patients; however, rates of virologic failure were higher without rivarin than with it.